Last 46 quarters of trend data · Healthcare · Medical - Care Facilities
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Cryo-Cell International, Inc.'s quarterly P/E stands at 13.1x, up 9.5% year-over-year. EV/EBITDA has compressed 61.8% YoY to 5.0x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 67.40 | 13.06 | 32.00 | 65.83 | — | 11.92 | 25.69 | 19.29 | — | 18.75 | 40.42 | 10.52 | 11.04 |
| — | +9.5% | +24.6% | +241.3% | — | -36.4% | -36.4% | +83.4% | — | -43.5% | +95.7% | -50.8% | — | |
| P/S Ratio | 0.85 | 1.21 | 1.31 | 2.03 | 2.22 | 1.57 | 2.10 | 1.37 | 1.42 | 1.59 | 1.30 | 1.03 | 1.19 |
| — | -22.8% | -37.6% | +48.7% | +56.6% | -1.2% | +61.8% | +32.6% | +18.6% | -21.1% | -24.3% | -57.9% | -67.5% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 7.53 | 3.80 | 16.14 | 18.16 | 8.83 | 5.98 | — | — | 8.19 | — | 76.73 | 6.36 | 3.78 |
| — | -36.5% | — | — | +7.9% | — | — | — | +116.8% | — | +860.2% | — | -80.7% | |
| EV / EBITDA | 9.97 | 5.02 | 6.36 | 14.04 | 96.24 | 13.13 | 12.80 | 13.80 | — | 9.80 | 8.72 | 4.91 | 11.41 |
| — | -61.8% | -50.4% | +1.8% | — | +34.1% | +46.8% | +181.0% | — | +3.8% | +12.5% | -46.2% | — | |
| EV / EBIT | 11.36 | 6.07 | 11.24 | 19.06 | — | — | 11.23 | 12.90 | — | 10.08 | 15.59 | 6.23 | 9.82 |
| — | — | +0.0% | +47.7% | — | — | -28.0% | +107.1% | — | -40.8% | +44.5% | -48.7% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Cryo-Cell International, Inc.'s operating margin was 24.3% in Q3 2025, up 5.5 pp QoQ and up 7.1 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 13.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 4.5% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.2% | 77.0% | 76.6% | 75.1% | 79.6% | 73.6% | 74.8% | 73.7% | 73.6% | 72.6% | 72.4% | 73.6% | 72.5% |
| — | +4.5% | +2.4% | +1.9% | +8.1% | +1.4% | +3.3% | +0.1% | +1.7% | +4.6% | +1.8% | +3.6% | +5.6% | |
| Operating Margin | 10.9% | 24.3% | 18.8% | 13.3% | -1.5% | 17.2% | 17.3% | 10.5% | -205.4% | 14.8% | 13.2% | 21.5% | 7.5% |
| — | +41.0% | +8.8% | +26.7% | +99.3% | +16.8% | +30.8% | -51.4% | -2841.2% | -17.1% | -15.5% | +6.2% | +166.5% | |
| Net Margin | 1.3% | 20.7% | 4.5% | 3.5% | -23.2% | 13.0% | 8.2% | 7.1% | -142.1% | 8.6% | 2.8% | 9.8% | 10.8% |
| — | +59.0% | -45.0% | -49.9% | +83.7% | +50.8% | +186.8% | -27.7% | -1416.5% | +42.3% | -65.8% | -14.5% | +223.9% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 0.6% | 2.5% | 0.6% | 0.4% | -2.9% | 1.7% | 1.1% | 0.9% | -17.1% | 1.0% | 0.3% | 1.2% | 1.3% |
| — | +51.7% | -47.7% | -51.6% | +82.9% | +70.6% | +222.2% | -22.7% | -1442.1% | +28.5% | -71.6% | -18.8% | +219.9% | |
| ROIC | — | — | — | — | -16.2% | 46.5% | 60.0% | 286.7% | -213.9% | 8.1% | 8.3% | 14.6% | 7.0% |
| — | — | — | — | +92.4% | +475.1% | +623.7% | +1868.6% | -3171.7% | -72.9% | -68.5% | -81.3% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Cryo-Cell International, Inc.'s Debt/EBITDA ratio is 2.0x, down from 4.6x last quarter — at a moderate level that warrants monitoring.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 3.26 | 2.02 | 4.59 | 9.93 | 59.58 | 9.91 | 8.68 | 11.76 | — | 7.90 | 7.97 | 5.16 | 11.28 |
| — | -79.6% | -47.1% | -15.6% | — | +25.4% | +8.9% | +127.8% | — | +51.6% | +1057.3% | +407.7% | — | |
| Current Ratio | 0.58 | 0.63 | 0.60 | 0.58 | 0.58 | 0.61 | 0.52 | 0.49 | 0.45 | 0.54 | 0.52 | 0.56 | 0.49 |
| — | +3.4% | +14.9% | +18.0% | +28.3% | +14.3% | -0.2% | -13.2% | -8.2% | +13.5% | -20.2% | -5.1% | -34.1% | |
| Quick Ratio | 0.55 | 0.60 | 0.57 | 0.54 | 0.55 | 0.57 | 0.49 | 0.45 | 0.42 | 0.48 | 0.48 | 0.51 | 0.45 |
| — | +4.8% | +17.1% | +20.8% | +32.3% | +19.2% | +1.5% | -12.8% | -7.4% | +10.5% | -20.3% | -4.0% | -36.2% | |
| Interest Coverage | 1.87 | 3.53 | 2.71 | 2.13 | -0.16 | 2.61 | 4.23 | 3.20 | — | 2.47 | 2.19 | 3.61 | 1.01 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCryo-Cell International, Inc.'s current P/E is 67.4x. The average P/E over the last 3 quarters is 37.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cryo-Cell International, Inc.'s current operating margin is 10.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cryo-Cell International, Inc.'s business trajectory between earnings reports.